Nerandomilast

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. It is a phosphodiesterase 4 (PDE4) inhibitor. It is taken by mouth. Common side effects include diarrhea, decreased weight, decreased appetite, and nausea. Nerandomilast was approved for medical use in the United States in October 2025. The US Food and Drug Administration considers it to be a first-in-class medication.

Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. It is a phosphodiesterase 4 (PDE4) inhibitor. It is taken by mouth. Common side effects include diarrhea, decreased weight, decreased appetite, and nausea. Nerandomilast was approved for medical use in the United States in October 2025. The US Food and Drug Administration considers it to be a first-in-class medication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1376634713 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

15 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.